دورية أكاديمية
Pan-TRK immunohistochemistry as screening tool for NTRK fusions: A diagnostic workflow for the identification of positive patients in clinical practice.
| العنوان: | Pan-TRK immunohistochemistry as screening tool for NTRK fusions: A diagnostic workflow for the identification of positive patients in clinical practice. |
|---|---|
| المؤلفون: | Vingiani A; Department of Diagnostic Innovation, Foundation IRCCS National Cancer Institute, Milan, Italy.; Department of Oncology and Hematoncology, University of Milan, Milan, Italy.; Department of Diagnostic Innovation, Foundation IRCCS National Cancer Institute, Milan, Italy., Lorenzini D; Department of Diagnostic Innovation, Foundation IRCCS National Cancer Institute, Milan, Italy.; Department of Diagnostic Innovation, Foundation IRCCS National Cancer Institute, Milan, Italy., Conca E; Department of Diagnostic Innovation, Foundation IRCCS National Cancer Institute, Milan, Italy.; Department of Diagnostic Innovation, Foundation IRCCS National Cancer Institute, Milan, Italy., Volpi CC; Department of Diagnostic Innovation, Foundation IRCCS National Cancer Institute, Milan, Italy., Trupia DV; Department of Diagnostic Innovation, Foundation IRCCS National Cancer Institute, Milan, Italy., Gloghini A; Department of Diagnostic Innovation, Foundation IRCCS National Cancer Institute, Milan, Italy., Perrone F; Department of Diagnostic Innovation, Foundation IRCCS National Cancer Institute, Milan, Italy., Tamborini E; Department of Diagnostic Innovation, Foundation IRCCS National Cancer Institute, Milan, Italy., Dagrada GP; Department of Diagnostic Innovation, Foundation IRCCS National Cancer Institute, Milan, Italy., Agnelli L; Department of Diagnostic Innovation, Foundation IRCCS National Cancer Institute, Milan, Italy., Capone I; Department of Diagnostic Innovation, Foundation IRCCS National Cancer Institute, Milan, Italy., Busico A; Department of Diagnostic Innovation, Foundation IRCCS National Cancer Institute, Milan, Italy.; Department of Oncology and Hematoncology, University of Milan, Milan, Italy., Pruneri G; Department of Diagnostic Innovation, Foundation IRCCS National Cancer Institute, Milan, Italy.; Department of Oncology and Hematoncology, University of Milan, Milan, Italy.; Department of Oncology and Hematoncology, University of Milan, Milan, Italy. |
| المصدر: | Cancer biomarkers : section A of Disease markers [Cancer Biomark] 2023; Vol. 38 (3), pp. 301-309. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: IOS Press Country of Publication: Netherlands NLM ID: 101256509 Publication Model: Print Cited Medium: Internet ISSN: 1875-8592 (Electronic) Linking ISSN: 15740153 NLM ISO Abbreviation: Cancer Biomark Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Amsterdam ; Washington, DC : IOS Press, c2005- |
| مواضيع طبية MeSH: | Lung Neoplasms*/diagnosis , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics, Humans ; Immunohistochemistry ; Prospective Studies ; Retrospective Studies ; Workflow |
| مستخلص: | Background: Pan-TRK inhibitors Entrectinib and Larotrectinib have been recently approved as tumor-agnostic therapies in NTRK1-2-3 rearranged patients and there is therefore an urgent need to identify reliable and accessible biomarkers for capturing NTRK fusions in the real-world practice. Objective: We aim to assess the analytical validity of the recently released pan-TRK assay (Ventana), running a head-to-head comparison between immunohistochemistry and Archer FusionPlex Lung Panel (ArcherDX) that is designed to detect key fusions in 13 genes, also including NTRK1-3. Methods: Pan-TRK IHC and NGS analysis were conducted on a retrospective/prospective cohort of 124 cancer patients (carcinomas, 93 cases; soft tissue sarcomas, 19; primary central nervous system tumours, 10; and neuroblastomas, 2). FISH data were available in most of the IHC/NGS discordant cases. Results: A comparison between IHC and NGS results was carried out in 117 cases: among 30 pan-TRK positive cases, NTRK rearrangement by NGS was found in 11 (37%), while one of the 87 (1.1%) pan-TRK negative cases (a case of NSCLC) showed a TPM3-NRTK1 rearrangement by NGS. Accordingly, sensitivity and specificity of IHC in predicting NTRK status were 91.7% and 81.9%, respectively, while negative (NPV) and positive predictive value (PPV) were 98.8% and 36.7%, respectively. Conclusions: These data lead to suggest that IHC with VENTANA pan-TRK antibody can be a reliable screening tool for the identification of patients potentially bearing NTRK rearranged tumours. |
| فهرسة مساهمة: | Keywords: Biomarker; Fluorescent in Situ Ibridization; NTRK; immunohistochemistry; next-generation sequencing |
| تواريخ الأحداث: | Date Created: 20230807 Date Completed: 20231122 Latest Revision: 20231122 |
| رمز التحديث: | 20231215 |
| DOI: | 10.3233/CBM-220357 |
| PMID: | 37545217 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1875-8592 |
|---|---|
| DOI: | 10.3233/CBM-220357 |